Spots Global Cancer Trial Database for Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer

Official Title: A Phase II Study of Pazopanib to Enable Partial Nephrectomy

Study ID: NCT01158521

Conditions

Clear Cell Renal Cell Carcinoma

Stage I Renal Cell Cancer

Stage II Renal Cell Cancer

Stage III Renal Cell Cancer

Interventions

pazopanib hydrochloride

therapeutic conventional surgery

Study Description

Brief Summary: RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pazopanib hydrochloride before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well pazopanib hydrochloride works when given before surgery in treating patients with kidney cancer.

Detailed Description: PRIMARY OBJECTIVES: I. To determine the rate of partial nephrectomy in patients with primary renal tumors otherwise requiring radical nephrectomy after neoadjuvant pazopanib treatment. SECONDARY OBJECTIVES: I. To determine the safety, tumor diameter/volume change, conversion of hilar to non-hilar tumors and surgical morbidity of neoadjuvant pazopanib for renal cell carcinoma (RCC). OUTLINE: Patients receive oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride. After completion of study treatment, patients are followed up for 1 year.